Pasithea Therapeutics Corp. Logo

Pasithea Therapeutics Corp.

Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.

KTTA | US

Overview

Corporate Details

ISIN(s):
US70261F1030
LEI:
Country:
United States of America
Address:
1111 LINCOLN ROAD, SUITE 500, 33139 MIAMI BEACH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company is dedicated to creating new therapeutics for complex neurological and psychiatric conditions with significant unmet medical needs. Its primary research pipeline targets treatments for Neurofibromatosis type 1 (NF1), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and schizophrenia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:04
Regulatory News Service
8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
English 145.9 KB

Automate Your Workflow. Get a real-time feed of all Pasithea Therapeutics Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pasithea Therapeutics Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pasithea Therapeutics Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ISU Abxis Co., Ltd. Logo
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea
086890
Iterum Therapeutics plc Logo
Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.
United States of America
ITRM
IVF HARTMANN Holding AG Logo
Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.
Switzerland
VBSN
Jade Biosciences, Inc. Logo
Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
United States of America
JBIO
Jaguar Health, Inc. Logo
Develops plant-based, non-opioid GI therapies for humans and animals.
United States of America
JAGX
Janux Therapeutics, Inc. Logo
Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.
United States of America
JANX
Japan Tissue Engineering Co., Ltd. Logo
Pioneers regenerative medicine with tissue products, CDMO services, and research models.
Japan
7774
Jasper Therapeutics, Inc. Logo
Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.
United States of America
JSPR
Jazz Pharmaceuticals plc Logo
Develops medicines for serious diseases in neuroscience and oncology.
United States of America
JAZZ
Develops therapies for rare genetic diseases, CNS disorders, and regenerative medicine.
Japan
4552

Talk to a Data Expert

Have a question? We'll get back to you promptly.